Expanded Access for AG-221

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

NCT00728520 ·Status: UNKNOWN ·Phase: PHASE2

Flotetuzumab Expanded Access Program

NCT04678466 ·Status: NO_LONGER_AVAILABLE

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

NCT03746912 ·Status: NO_LONGER_AVAILABLE

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

NCT02577406 ·Status: COMPLETED ·Phase: PHASE3

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

NCT00071006 ·Status: COMPLETED ·Phase: PHASE2

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

NCT02074839 ·Status: RECRUITING ·Phase: PHASE1

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

NCT03030612 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

NCT03245424 ·Status: APPROVED_FOR_MARKETING

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

NCT01018069 ·Status: TERMINATED ·Phase: PHASE2

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

NCT00146120 ·Status: COMPLETED ·Phase: PHASE3

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate

NCT02067143 ·Status: COMPLETED ·Phase: PHASE2

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

NCT00048958 ·Status: ACTIVE_NOT_RECRUITING

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

NCT02920008 ·Status: COMPLETED ·Phase: PHASE3

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

NCT01311258 ·Status: RECRUITING

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

NCT04358393 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

NCT04484363 ·Status: NO_LONGER_AVAILABLE

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

NCT03588078 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

NCT00502385 ·Status: COMPLETED ·Phase: PHASE1

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

NCT03573024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

NCT00898456 ·Status: ACTIVE_NOT_RECRUITING

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

NCT03744390 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

NCT00766116 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Treatment of Adult ALL With an MRD-directed Programme.

NCT00358072 ·Status: COMPLETED ·Phase: PHASE2

Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.

NCT03311815 ·Status: COMPLETED